A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma

NCT01271803 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

131

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Cobimetinib
DRUG: vemurafenib

Sponsor

Hoffmann-La Roche